Folkman J: Tumor angiogenesis. Adv Cancer Res (19): 331–358, 1974.
O'Meara RAQ, Jackson RD: Cytological observations on carcinoma. Irish J Med Sci (6): 327–328, 1958.
O'Meara RAQ: Coagulative properties of cancers. Irish J Med Sci (6): 474–479, 1958.
Fischer A: Beitrag zur Biologie der Gewebezellen. Eine vergleichendbiologische Studie der normalen und malignen Gewebezellen in vitro. Arch Entwicklungsmech Org (104): 210, 1925.
Christman JK, Silverstein SC, Acs G: Plasminogen activators. In: Barret AS (ed) Mammalian cells and tissue. New York, North Holland, 1977, pp 91–149.
Trosseau A: Phlegmasia alba dolens. Clinique médicale de l'Hôtel-Dieu de Paris. London New Sydenham Soc (3): 94, 1865.
Peck SD, Reiquam CW: Disseminated intravascular coagulation in cancer patients: supportive evidence. Cancer (31): 1114–1119, 1973.
Ambrus JL, Ambrus CM, Pickern J, Soldes S, Bross I: Hematologic changes and thromboembolic complications in neoplastic disease and their relationship to metastasis. J Med (6): 433–458, 1975.
Sack GH, Levin J, Bell WR: Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, patho-physiologic, and therapeutic features. Medicine (56): 1–37, 1977.
Rasche H, Dietrich M: Hemostatic abnormalities associated with malignant diseases. Eur J Cancer (13): 1053–1064, 1977.
Lyman GH, Bettigole RE, Robson E, Ambrus JL, Urban H: Fibrinogen kinetics in patients with neoplastic disease. Cancer (41): 1113–1122, 1978.
Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ, Forcier RJ, Harrower HW, Johnson RO: Rationale and experimental design for the VA cooperative study of anti-coagulation (Warfarin) in the treatment of cancer. Cancer (44): 732–741, 1979.
Donati MB, Poggi A: Malignancy and haemostasis. Br J Haematol (44): 173–182, 1980.
Wajima T: Thrombophlebitis in cancer patients. Ann NY Acad Sci (370): 138–144, 1981.
Edwards RL, Rickles FR, Cronlund M: Abnormalities of blood coagulation in patients with cancer. J Lab Clin Med (98): 917–928, 1981.
Edwards RL, Rickles FR, Bobrove AM: Monoculear cell tissue factor: cell of origin and requirements for activation. Blood (54): 359–370, 1979.
Gore JM, Appelbaum JS, Greene HL, Dexter L, Dalen JE: Occult cancer in patients with acute pulmonary embolism. Ann Intern Med (96): 556–560, 1982.
Gitlin D, Craig JM: Variations in the staining characteristics of human fibrin. Am J Pathol (33): 267–283, 1957.
Day ED, Planinsek JA, Pressman D: Localization in vivo of radioiodinated anti-rat-fibrin antibodies and radioiodinated rat fibrinogen in the Murphy rat lymphosarcoma and in other transplantable rat tumors. J Natl Cancer Inst (22): 413–426, 1959.
Marrack D, Kubala M, Corry P, Leavens M, Howze J, Dewey W, Bale WF, Spar IL: Localization of intracranial tumors: comparative study with 131I-labeled antibody to human fibrinogen and neohydrin-203Hg. Cancer (20): 751–755, 1967.
Spar IL, Bale WF, Marrack D, Dewey WC, McCardle RJ, Harper PV: 131I-Labeled antibodies to human fibrinogen: diagnostic studies and therapeutic trials. Cancer (20): 865–870, 1967.
Hiramoto R, Yagi Y, Pressman D: Immunohistochemical studies of antibodies in anti-Murphy lymphosarcoma sera. Cancer Res (19): 874–879, 1959.
Hiramoto R, Bernecky J, Jurandowski J, Pressman D: Fibrin in human tumors. Cancer Res (20): 592–593, 1960.
Kodama Y, Tanaka K: Thromboplastic and fibrinolytic activities of V2 and V7 carcinomas of rabbit, with special reference to fibrin deposition and thrombus formation in the tumors. Acta Pathol Jap (28): 279–286, 1978.
Chew EC, Wallace AC: Demonstration of fibrin in early stages of experimental metastases. Cancer Res (36): 1904–1909, 1976.
Wood S, Holyoke ED, Yardly JH: Mechanisms of metastasis production by blood-borne cancer cells. Can Cancer Conf (4): 167–221, 1961.
Kinjo M: Lodgement and extravasation of tumour cells in blood-borne metastasis: an electron microscope study. Br J Cancer (38): 293–300, 1978.
Dvorak HF, Galli SJ, Dvorak AM: Expression of cell-mediated hypersensitivity in vivo—recent advances. Int Rev Exp Pathol (21): 119–194, 1980.
Harris NL, Dvorak AM, Smith J, Dvorak HF: Fibrin deposits in Hodgkin's disease. Am J Pathol (108): 119–129, 1982.
Grinnell F: Cellular adhesiveness and extracellular substrata. Int Rev Cytol (53): 65–144, 1978.
Hynes RO: Relationship between fibronectin and the cytoskeleton. In: Poste G, Nicolson GL (eds) Cytoskeletal elements and plasma membrane organization. Cell surface reviews, Vol 7. New York, Elsevier/North Holland, 1981.
Mosher DF: Fibronectin. Prog Hemostasis Thromb (5): 111–151, 1980.
Vaheri A, Mosher DF: High molecular weight, cell surface-associated glycoprotein (fibronectin) lost in malignant transformation. Biochem Biophys Acta (516): 1–25, 1978.
Yamada K, Olden K: Fibronectins: adhesive glycoproteins of cell surface and blood. Nature (275): 179–184, 1978.
Doolittle RF, Bouma H, Cottrell BA, Strong D, Watt KWK: The covalent structure of human fibrinogen. In: Bing DH (ed) The chemistry and physiology of the human plasma proteins. New York, Pergamon Press, 1979, pp. 77–95.
Nossel HL: Radioimmunoassay of fibrinopeptides in relation to intravascular coagulation and thrombosis. New Engl J Med (295): 428–432, 1981.
Davie EW, Fujikawa K, Kurachi K, Kisiel W: The role of serine proteases in the blood coagulation cascade. Adv Enzymol (48): 277–318, 1979.
Zimmerman TS, Fierer J, Rothberger H: Blood coagulation and the inflammatory response. Semin Hematol (14): 391–408, 1977.
Folk JE, Finlayson JS: The ε-(γ-glutamyl) lysine crosslink and the catalytic role of transglutaminases. Adv Protein Chem (31): 1–133, 1977.
Hermans J, McDonagh J: Fibrin: structure and interactions. Semin Thromb Hemostas (8): 11–24, 1982.
Lopaciuk S, McDonagh RP, McDonagh J: Comparative studies on blood coagulation factor XIII. Proc Soc Exp Biol Med (158): 68–72, 1978.
Robbins KC, Wohl RC, Summaria L: Plasmin and plasminogen activators: kinetics, and kinetics of plasminogen activation. Ann N Y Acad Sci (370): 588–591, 1981.
Reich E: Plasminogen activator: secretion by neoplastic cells and macrophages. In: Reich E, Rifkin DB, Shaw E (eds) Proteases and biological control. New York, Cold Spring Harbor, 1975.
Wiman B, Collen D: Molecular mechanism of physiological fibrinolysis. Nature (272): 549–550, 1978.
Marder VJ, Budzynski AZ: Data for defining fibrinogen and its plasmic degradation products. Thromb Diathes Haemorrh (Stuttgart (33): 199–207, 1975.
Osbabr AJ, Gladner JA, Laki K: Studies on the physiological activity of the peptide released during the fibrinogen-fibrin conversion. Biochim Biophys Acta (86): 535–542, 1964.
Stecher VJ, Sorkin E: The chemotactic activity of fibrin lysis products. Int Arch Allergy (43): 879–886, 1972.
Kay AB, Pepper DS, Ewart MR: Generation of chemotactic activity for leukocytes by the action of thrombin on human fibrinogen. Nat New Biol (243): 56–57, 1973.
Girmann G, Pees H, Schwarze G, Scheurlen PG: Immunosuppression by micromolecular fibrinogen degradation products in cancer. Nature (259): 399–401, 1976.
Richardson DL, Pepper DS, Kay AB: Chemotaxis for human monocytes by fibrinogen-derived peptides. Br J Haematol (32): 507–513, 1976.
Belew M, Gerdin B, Porath J, Saldeen T: Isolation of vasoactive peptides from human fibrin and fibrinogen degraded by plasmin. Thromb Res (13): 983–994, 1978.
Gerdin B, Saldeen T: Effect of fibrin degradation products on microvascular permeability. Thromb Res (13): 995–1006, 1978.
Krzystyniak K, Stachurska J, Ryzewski J, Bykowska K, Kopec M: Suppressive effect of low molecular weight fibrinogen degradation products on human and rat lymphocytes. Thromb Res (12): 523–530, 1978.
Belew M, Gerdin B, Lindeberg G, Porath J, Saldeen T, Wallin R: Structure-activity relationships of vasoactive peptides derived from fibrin or fibrinogen degraded by plasmin. Biochim Biophys Acta (621): 169–178, 1980.
Plow EF, Freaney D, Edgington TS: Inhibition of lymphocyte protein synthesis by fibrinogen-derived peptides. J Immunol (128): 1595–1599, 1982.
Francis CW, Marder VJ, Barlow GH: Plasmic degradation of crosslinked fibrin: characterization of new macromolecular soluble complexes and a model of their structure. J Clin Invest (66): 1033–1043, 1980.
Colvin RB, Dvorak HF: Role of the clotting system in cell-mediated hypersensitivity. J Immunol (114): 377–387, 1975.
Dvorak HF, Mihm MCJr: Basophilic leukocytes in allergic contact dermatitis. J Exp Med (135): 235–254, 1972.
Colvin RB, Johnson RA, Mihm MCJr, Dvorak HF: Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J Exp Med (138): 686–698, 1973.
Kashgarian M, Hayslett JP, Spargo BH: Renal Disease. Am J Pathol (89): 187–272, 1977.
Dvorak HF, Dickersin GR, Dvorak AM, Manseau EJ, Pyne K: Human breast carcinoma. Fibrin deposits and desmoplasia. Inflammatory cell type and distribution. Microvasculature and infarction. J Natl Cancer Inst (67): 335–345, 1981.
Rosas-Uribe A, Variakojis D, Rappaport H: Proteinacious precipitate in nodular (follicular) lymphomas. Cancer (31): 534–542, 1973.
Talerman A, Platenburg HPJM: Follicular lymphoma with deposits of amorphous hyaline material. J Pathol (112): 27–31, 1974.
Cooper JH, Haq BM, Bagnell H: Intrafollicular hyalinosis and arterial hyalinosis of the spleen: histochemical and immunofluorescence studies. J Pathol (98): 193–199, 1969.
Resnick GD, Nachman RL: Reed-Sternberg cells in Hodgkin's disease contain fibronectin. Blood (57): 339–342, 1981.
Dvorak HF, Orenstein NS, Carvalho AC, Churchill WH, Dvorak AM, Galli SJ, Feder J, Bitzer AM, Rypsyc J, Giovinco P: Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol (122): 166–174, 1979.
Dvorak HF, Dvorak AM, Manseau EJ, Wiberg L, Churchill WH: Fibrin-gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. J Natl Cancer Inst (62): 1459–1472, 1979.
Churchill WHJr, Rapp HJ, Kronman BS, Borsos T: Detection of antigens of a new diethylnitrosamine-induced transplantable hepatoma by delayed hypersensitivity. J Natl Cancer Inst (41): 13–29, 1968.
Asch BB, Dvorak HF, Senger DR: A major phospho-protein marker for neoplastic transformation of fibroblastic and epithelial cells. Cold Spring Harbor Conferences on Cell Proliferation, vol 9, 1982, 365–369.
Dvorak HF, Quay SC, Orenstein NS, Dvorak AM, Hahn P, Bitzer AM, Carvalho AC: Tumor shedding and coagulation. Science (212): 923–924, 1981.
Dvorak HF, Mihm MCJr, Dvorak AM, Barnes BA, Manseau EJ, Galli SJ: Rejection of first-set skin allografts in man. The microvasculature is the critical target of the immune reponse. J Exp Med (150): 322–337, 1979.
Dvorak HF, Dvorak AM, Churchill WHJr: Immunologic rejection of diethylnitrosamine-induced hepatomas in strain 2 guinea pigs. Participation of basophilic leukocytes and macrophage aggregates. J Exp Med (137): 751–775, 1973.
Dvorak HF, Orenstein NS, Dvorak AM: Tumor-secreted mediators and the tumor microenvironment: relationship to immunological surveillance. Lymphokines (2): 203–233, 1981.
Adelman NE, Hammond ME, Cohen S, Dvorak HF: Lymphokines as inflammatory mediators. In: Pick E, Oppenheim J, Cohen S (eds) The biology of lymphokines. New York, Academic Press, 1979, pp. 13–58.
DeWeck AL, Kristensen F, Landy M: Biochemical characterization of lymphokines. Academic Press, New York, 1980, pp 1–622.
Dvorak HF, Dvorak AM: Immunohistologic characterization of inflammatory cells that infiltrate tumors. In: Haskill JS (ed) Tumor immunity in prognosis: the role of mononuclear cell infiltration. New York, Marcel Dekker, Inc, 1982, 279–307.
Johnston MM, Greenbaum LM: Leukokinin-forming system in the ascitic fluid of a murine mastocytoma. Biochem Pharmacol (22): 1386–1389, 1973.
Greenbaum LM, Semente G, Prakash A, Roffman S: Leukokinins; their pharmacological properties and role in the pathology of fluid (ascites) accumulation. Agents Actions (8): 80–84, 1978.
Grebow P, Prakash A, Greenbaum L: Leukokinin-H generated from human ascites fluid: its isolation and pharmacology. Agents Actions (9): 265–274, 1979.
Greenbaum LM: Kininogenases of blood cells (alternate kinin generating systems). In: Erdos EG (ed) Handbook of experimental pharmacology, vol 25, Suppl, 1979, pp. 91–102.
Roffman S, Greenbaum L: Properties of leukokininogen isolated from human neoplastic ascites. Biochem Pharmacol (28): 1043–1050, 1979.
Greenbaum LM, Grebow P, Johnston M, Prakash A, Semente G: Pepstatin, an inhibitor of leukokinin formation and ascitic fluid accumulation. Cancer Res (35): 706–710, 1975.
Greenbaum LM: Pepstatin, an inhibitor of acid kininogenases and ascites retardant in neoplastic disease. Fed Proc (38): 2788–2791, 1979.
Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Vascular permeability factor (VPF): a protein secreted by tumors that causes ascites fluid accumulation. Fed Proc (41): 964, 1982 (abstract).
Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes ascites fluid accumulation Science, 1983 (in press).
Aukland K, Nicolaysen G: Interstitial fluid volume: local regulatory mechanisms. Physiol Rev (61): 556–643, 1981.
Butler TP, Grantham FH, Gullino PM: Bulk transfer of fluid in the interstitial compartment of mammary tumors. Cancer Res (35): 3084–3088, 1975.
Maillard JL, Pick E, Turk JL: Interaction between ‘sensitized lymphocytes’ and antigen in vitro. V. Vascular permeability induced by skin-reactive factor. Int Arch Allergy (42): 50–68, 1972.
Willoughby DA, Boughton B, Schild HO: A factor capable of increasing vascular permeability present in lymph node cells. A possible mediator of the delayed reaction. Immunol (6): 484–498, 1963.
Sobel A, LaGrue G: Role of a vascular permeability-increasing factor released by lymphocytes in renal pathology. Lymphokine Rep (1): 211–230, 1980.
Semeraro N, Donati MB: Pathways of blood clotting initiation by cancer cells. In: Donati MB, Davidson JF, Garattini S (eds) Malignancy and the hemostatic system. New York, Raven Press, 1981, pp. 65–81.
Boggust WA, O'Meara RAQ, Fullerton WW: Diffusible thromboplastins of human cancer and chorion tissue. Eur J Cancer (3): 467–473, 1968.
Frank AL, Holyoke ED: Tumor fluid thromboplastin activity. J Cancer (3): 677–682, 1968.
Gasic GJ, Koch PAG, Hsui B, Gasic TB, Niewiarowski S: Thrombogenic activity of mouse and human tumors: effect on platelets, coagulation, and fibrinolysis, and possible significance for metastasis. Z Krebforsch (86): 263–277, 1967.
Gordon SG, Cross BA: A factor X-activating cysteine protease from malignant tissue. J Clin Invest (67): 1665–1671, 1981.
Holyoke ED, Ichihashi H: The C3H/St/Ha mammary tumor. I. Stabilizing enzymes from the mouse tumor YPC-1. Biochem Biophys Res Com (24): 776–781, 1966.
Khato J, Suzuki M, Sato H: Quantitative study on thromboplastin in various strains of Yoshida ascites hepatoma cells of rat. Gann (65): 289–294, 1974.
Kinjo M, Oka K, Naito S, Kohga S, Tanaka K, Oboshi S, Yahata Y, Yasumoto K: Thromboplastic and fibrinolytic activities of cultured human cancer cell lines. Br J Cancer (39): 15–23, 1979.
Laki K, Tyler HM, Yancey ST: Clot forming and clot stabilizing enzymes from the mouse tumor YPC-1. Biochem Biophys Res Com (24): 776–781, 1966.
Peterson HI, Zettertren L: Thromboplastic and fibrinolytic properties of three transplantable rat tumors. Acta Chir Scand (136): 365–368, 1970.
Sakuragawa N, Takahashi K, Hoshiyama M, Jimbo C, Ashizawa K, Matsuoka M, Ohnishi Y: The extract from the tissue of gastric cancer as procoagulant in disseminated intravascular coagulation syndrome. Thromb Res (10): 457–463, 1977.
Svanberg L: Thromboplastic activity of human ovarian tumors. Thromb Res (6): 307–313, 1975.
Zacharski LR, McIntyre OR: Tissue factor (thromboplastin, factor III) synthesis by cultured cells. J Med (4): 118–131, 1973.
Green D, Ryan C, Malandruccolo N, Nadler HL: Characterization of the coagulant activity of cultured human fibroblasts. Blood (37): 47–51, 1971.
Maynard JR, Fintel DJ, Pitlick FA, Nemerson Y: Tissue factor in cultured cells. Metabolic control. Lab Invest (35): 542–549, 1976.
Cattan A, Bresson ML: Murine tumor cell activity on in vitro hemostasis. Biomedicine (25): 252–254, 1976.
Curatolo L, Colucci M, Cambini AL, Poggi A, Morasca L, Donati MB, Semeraro N: Evidence that cells from experimental tumours can activate coagulation factor X. Br J Cancer (40): 228–233, 1979.
Dvorak HF, Van De Water L, Dvorak AM, Harvey VS, Anderson D, De Wolf W, Bach R: Human tumor cells and guinea pig macrophages shed plasma membrane derived vesicles with procoagulant activity. Fed Proc (41): 8, 1982 (abstract).
Gordon SG, Lewis BJ: Comparison of procoagulant activity in tissue culture medium from normal and transformed fibroblasts. Cancer Res (38): 2467–2472, 1978.
Nemerson Y, Zur M, Bach R, Gentry R: The mechanism of action of tissue factor: a provisional model. In: Mann KG, Taylor FB (eds) The regulation of coagulation. New York. Elsevier/North Holland, 1980, pp 193–202.
Bach R, Nemerson Y, Konigsberg W: Purification and characterization of bovine tissue factor. J Biol Chem (256): 8324–8331, 1981.
Gralnick HR, Abrell E: Studies on the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukaemia. Br J Haematol (24): 89–99, 1973.
Gralnick HR, Tan HK: Acute promyelocytic leukemia. A model for understanding the role of the malignant cell in hemostasis. Hum Pathol (5): 661–673, 1974.
Green D, Ryan C, Malandrucculo N, Nadler HL: Characterization of the coagulant activity of cultured human fibroblasts. Blood (37): 47–51, 1971.
Zacharski LR, McIntyre OR: Physical stability of cell culture procoagulants detectable in first-stage coagulation factor assays. Proc Soc Exp Biol Med (139): 713–715, 1972.
Maynard JR, Heckman CA, Pitlick FA, Nemerson Y: Association of tissue factor activity with the surface of cultured cells. J Clin Invest (55): 814–824, 1975.
Maynard JR, Dreyer BE, Stemerman MB, Pitlick FA: Tissue-factor coagulant activity of cultured human endothelial and smooth muscle cells and fibroblasts. Blood (50): 387–396, 1977.
Kadish JL, Wenc KM, Dvorak HF: Tissue factor activity of normal and neoplastic cells: quantitation and species specificity. J Natl Cancer Inst, 1983 (in press).
Stormorken H: Species differences of clotting factors in ox, dog, horse, and man. Theomboblastin and proconvertin. Acta Physiol Scand (41): 301–324, 1957.
Lyberg T, Hetland O, Prydz H: Synthesis of thromboplastin protein by a murine macrophage-like cell line. Thromb Haemostas (47): 154–156, 1982.
Pineo GF, Regoeczi E, Hatton MWC, Brain MC: The activation of coagulation by extracts of mucus: a possible pathway of intravascular coagulation accompanying adenocarcinomas. J Lab Clin Med (82): 255–266, 1973.
Pineo GF, Brain MC, Gallus AS, Hirsh J, Hatton MWC, Regoeczi E: Tumors, mucus production, and hypercoagulability. Ann N Y Acad Sci (230): 262–270, 1974.
Gordon SG, Franks JJ, Lewis B: Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thromb Res (6): 127–137, 1975.
Gordon SG, Franks JJ, Lewis BJ: Comparison of procoagulant activities in extracts of normal and malignant human tissue. J Natl Cancer Inst (62): 773–776, 1979.
Gordon SG: A proteolytic procoagulant associated with malignant transformation. J Histochem Cytochem (29): 457–463, 1981.
Colucci M, Curatolo L, Donati MB, Semeraro N: Cancer cell procoagulant activity: evaluation by an amidolytic assay. Thromb Res (18): 589–595, 1980.
Black PH: Shedding from the cell surface of normal and cancer cells. Adv Cancer Res (32): 75–199, 1980.
Doljanski F, Kapeller M. Cell surface shedding — the phenomenon and its possible significance. J Theor Biol (62): 253–270, 1976.
Calafat J, Hilgers J, Van Blitterswijk WJ, Verbeet M, Hageman PC: Antibody-induced modulation and shedding of mammary tumor virus antigens on the surfaces of GR ascites leukemia cells as compared with normal antigens. J Natl Cancer Inst (56): 1019–1029, 1976.
Bystryn J-C: Release of cell-surface tumor-associated antigens by viable melanoma cells from humans. J Natl Cancer Inst (59): 325–328, 1977.
Koch GLE, Smith MJ: An association between actin and the major histocompatibility antigen H-2. Nature (273): 274–277, 1978.
Raz A, Goldman R, Yuli I, Inbar M: Isolation of plasma membrane fragments and vesicles from ascites fluid of lymphoma-bearing mice and their possible role in the escape mechanism of tumors from host immune rejection. Cancer Immunol Immunother (4): 53–59, 1978.
Gasic GJ, Boettiger D, Catalfamo JL, Gasic TB, Steward GJ: Aggregation of platelets and cell membrane vesiculation by rat cells transformed in vitro by Rous sarcoma virus. Cancer Res (38): 2950–2955, 1978.
Bitzer AM, Carvalho ACA, Davis GL, Dvorak HF: PCA10 Procoagulant released by line 10 tumor cells in culture. Fed Proc (41): 780, 1981 (abstract).
Dvorak HF, Van de Water L, Bitzer AM, Dvorak AM, Anderson D, Harvey VS, Bach R, DeWolf W, Carvalho ACA: Tumor cells shed plasma membrane vesicles with procoagulant activity in short term tissue culture (submitted for publication).
Dunkel VC, Bast RC, Gerwin BI, Heine V, Cotter-Fox M, Borsos T: Presence of A-type and absence of C-type virus particles in a chemically induced guinea pig hepatoma. J Natl Cancer Inst (53): 591–593, 1974.
Pitlick FA, Nemerson Y: Purification and characterization of tissue factor apoprotein. Meth Enzymol (40): 37–48, 1976.
Jordan RE, Oosta GM, Gardner WT, Rosenberg RD: The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem (255): 10081–10090, 1980.
Laki K, Tyler HM, Yancey ST: Clot forming and clot stabilizing enzymes from the mouse tumor YPC-1. Biochem Biophys Res Comm (24): 776–781, 1966.
Colvin RB, Mosesson MW, Dvorak HF: Delayed-type hypersensitivity skin reactions in congenital afibrinogenemia lack fibrin deposition and induration. J Clin Invest (63): 1302–1306, 1979.
Rickles FR, Hardin JA, Pitlick FA, Hoyer LW, Conrad ME: Tissue factor activity in lymphocyte cultures from normal individuals and patients with hemophilia A. J Clin Invest (52): 1427–1434, 1973.
Rothberger H, Zimmerman S, Spiegelberg HL, Vaughan JH: Leukocyte procoagulant activity. Enhancement of production in vitro by IgG and antigen-antibody complexes. J Clin Invest (59): 549–557, 1977.
Edwards RL, Rickles FR: Delayed hypersensitivity in man: effects of systemic anticoagulation. Science (200): 541–543, 1978.
Gezy CL, Hopper KE: A mechanism of migration inhibition in delayed-type hypersensitivity reactions. II. Lymphokines promote procoagulant activity of macrophages in vitro. J Immunol (126): 1059–1065, 1981.
Levy GA, Schwartz BS, Edgington TS: The kinetics and metabolic requirements for direct lymphocyte induction of human procoagulant monokines by bacterial lipopolysaccharide. J Immunol (127): 357–363, 1981.
Rothberger H, Zimmerman TS, Vaughan JH: Increased production and expression of tissue thromboplastin-like procoagulant activity in vitro by allogeneically stimulated human leukocytes. J Clin Invest (62): 649–655, 1978.
Genco P, Bettigole R, Yoshida T, Cohen S: A factor with procoagulant activity produced by stimulated human leukocyte cultures. Clin Immunol Immunopathol (17): 363–371, 1980.
Edwards RL, Rickles FR, Bobrove AM: Mononuclear cell tissue factor: cell of origin and requirements for activation. Blood (54): 359–370, 1979.
Edwards RL, Rickles FR: The role of human T cells (and T cell products) for monocyte tissue factor generation. J Immunol (125): 606–609, 1980.
Edwards RL, Rickles FR: The role of monocyte tissue factor in the immune response. Lymphokine Rep (1): 181–210, 1980.
Schwartz BS, Edgington TS: Immune complex-induced human monocyte procoagulant activity. I. A Rapid unidirectional lymphocyte-instructed pathway. J Exp Med (154): 892–906, 1981.
Schwartz BS, Levy GA, Edgington TS: Immune complex induced human monocyte procoagulant activity. II. Cellular kinetics and metabolic requirements. J Immunol (128): 1037–1042, 1982.
Geczy CL, Meyer PA: Leukocyte procoagulant activity in man: an in vitro correlate of delayed-type hypersensitivity. J Immunol (128): 331–335, 1982.
Chen LB, Buchanan JM: Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc Nat Acad Sci (72): 131–135, 1975.
Glenn KC, Carney DH, Fenton JWII, Cunningham DD: Thrombin active site regions required for fibroblast receptor binding and initiation of cell division. J Biol Chem (255): 6609–6616, 1980.
Ratnoff OD: Some relationships among hemotasis, fibrinolytic phenomena, immunity, and the inflammatory response. Adv Immunol (10): 145–277, 1969.
Colman RW, Osbahr AJ, Morris RE: New vasoconstrictor, bovine peptide B, released during blood coagulation. Nature (215): 292–293, 1967.
Postlethwaite AE, Keski-Oja J, Balian G, Kang AH: Induction of fibroblast chemotaxis by fibronectin. Localization of the chemotactic region to a 140,000-molecular weight non-gelatin-binding fragment. J Exp Med (153): 494–499, 1981.
Bowerson JC, Sorgente N: Chemotactic response of vascular endothelial cells to fibronectin. J Cell Biol (87): 64a, 1980 (abstract).
Tsukamoto Y, Helsel WE, Wahl SM: Macrophage production of fibronectin, a chemoattractant for fibroblasts. J Immunol (127): 673–678, 1981.
Atherton BT, Hynes RO: A difference between plasma and cellular fibronectin located with monoclonal antibodies. Cell (25): 133–141, 1981.
Pierschbacher MD, Hayman EG, Ruoslahti E: Location of the cell-attachment site in fibronectin with monoclonal antibodies and proteolytic fragments of the molecule. Cell (26): 259–267, 1981.
Hayashi M, Yamada KM: Differences in domain structures between plasma and cellular fibronectins. J Biol Chem (256): 11292–11300, 1981.
Ryan JJ, Ketcham AS, Wexler H: Warfarin treatment of mice bearing autochthonous tumors: effect on spontaneous metastases. Science (162): 1493–1494, 1968.
Editorial. Fibrin and cancer. Br Med J (4): 641–642, 1971.
Brown JM: A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases. Cancer Res (33): 1217–1224, 1973.
Hilgard P, Thornes RD: Anticoagulants in the treatment of cancer. Eur J Cancer (12): 755–762, 1976.
Hoover HC, Ketchman AS: Techniques for inhibiting tumor metastases. Cancer (35): 5–14, 1975.
Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ, Forcier RJ, Edwards R, Headley E, Kim S-H, O'Donnell JR, O'Dell R, Tornyos K, Kwaan HC: Effect of warfarin on survival in small cell carcinoma of the lung. JAMA (245): 831–835, 1981.
Gralnick HR: Cancer cell procoagulant activity. In: Donati MB, Davidson JF, Garattini S (eds) Malignancy and the hemostatic system. New York, Raven press, 1981. pp 57–63.
Hilgard P: The use of one anticoagulant in tumor therapy. In: Donati MB, Davidson JF, Garattini S (eds) Malignancy and the hemostatic system. New York, Raven press, 1981, pp. 103–111.